Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Laserscope

This article was originally published in The Gray Sheet

Executive Summary

Laserscope Aura: Firm is gearing up to begin shipments of the surgical and dermatological laser system in October following April 510(k) clearance by FDA. The device, which fills out the firm's exisiting line of lasers with dermatologic applications including the Orion and 800 Series systems, will be targeted at the physician's office and outpatient surgery markets. In the dermatology area, Laserscope says the Aura can be used to treat "vascular lesions such as leg veins, hemangiomas, birth marks and facial spider veins, as well as benign occurrences such as brown sun spots, liver spots, skin tags, warts and moles." The device also can be used for ear, nose and throat applications, Laserscope says. The company plans to sell the system through its 30-person direct sales force in the U.S., U.K, and France, and through distributors in other countries. Aura can be used in combination with Laserscope's SmartScan microprocessor-controlled dermatologic scanning device, introduced last year, and will be priced between $49,000 and $70,000...

You may also be interested in...



Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004497

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel